Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993353 · ClinicalTrials.gov registry record · Phase 2
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
A Phase 2 study of Cancer and Head and Neck Cancer, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03993353: Completed Phase 2 study of Cancer and Head and Neck Cancer, sponsored by University of California, San Diego.
NCT03993353 is a Phase 2 study of Cancer and Head and Neck Cancer that has completed, run by University of California, San Diego. The registered enrollment target is 7 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03993353, a Phase 2 study of Cancer and Head and Neck Cancer, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Primary Outcome
Rate of dose limiting toxicity at least possibly attributable to study treatment
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Tadalafil
Study Locations (1)
California
- UCSD Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 2 |
What the finished NCT03993353 record still lists
NCT03993353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03993353 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03993353 about?
NCT03993353 is a clinical study titled "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer". This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
What is the current status of trial NCT03993353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-04-07. Estimated completion is 2024-01-09.
What conditions does trial NCT03993353 study?
This clinical trial studies the following conditions: Cancer, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Cancer Metastatic.
What interventions are being tested in trial NCT03993353?
The interventions under investigation include: Pembrolizumab (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT03993353?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03993353 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03993353's enrollment target sits among peer trials
7 609th of 615 higher than 5 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI